Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs1016343
rs1016343
T 0.700 GeneticVariation GWASCAT Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. 17401366

2007

dbSNP: rs10165970
rs10165970
0.010 GeneticVariation BEFREE Study distribution by tumor was as follows: breast cancer (n=15), prostate cancer (n=3), pancreatic cancer (n=2), non-Hodgkin's lymphoma (n=2), glioma (n=1), chronic lymphocytic leukemia (n=1), colorectal cancer (n=1), non-small cell lung cancer (n=1) and ovarian cancer (n=1).We identified 10 single nucleotide polymorphisms (SNPs) significantly associated with cancer risk: NPAS2 rs10165970 (mixed and breast cancer shiftworkers), rs895520 (mixed), rs17024869 (breast) and rs7581886 (breast); CLOCK rs3749474 (breast) and rs11943456 (breast); RORA rs7164773 (breast and breast cancer postmenopausal), rs10519097 (breast); RORB rs7867494 (breast cancer postmenopausal), PER3 rs1012477 (breast cancer subgroups) and assessed the level of quality evidence to be intermediate. 28177907

2017

dbSNP: rs10175368
rs10175368
0.010 GeneticVariation BEFREE These results demonstrate smoking and alcohol consumption to modify the risks of CYP1B1 polymorphisms for prostate cancer which may be through rs10175368, and this is of importance in understanding their role in the pathogenesis and as a biomarker for this disease. 30133114

2018

dbSNP: rs10187424
rs10187424
T 0.700 GeneticVariation GWASCAT Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. 29892016

2018

dbSNP: rs10187424
rs10187424
A 0.700 GeneticVariation GWASCAT Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. 21743467

2011

dbSNP: rs10187424
rs10187424
A 0.700 GeneticVariation GWASCAT A large multiethnic genome-wide association study of prostate cancer identifies novel risk variants and substantial ethnic differences. 26034056

2015

dbSNP: rs10194115
rs10194115
0.700 GeneticVariation GWASCAT Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer. 20932654

2010

dbSNP: rs1024611
rs1024611
0.010 GeneticVariation BEFREE We performed a case-control study to analyze the frequencies of CCL2 (I/D, rs3917887), -2518 (A > G, rs1024611), and CCR2 (G > A, rs1799864) polymorphisms for prostate cancer (PCa) risk. 25266801

2015

dbSNP: rs1031588
rs1031588
G 0.700 GeneticVariation GWASCAT Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. 17401366

2007

dbSNP: rs103294
rs103294
0.730 GeneticVariation BEFREE In addition to confirming several associations reported in other ancestry groups, this study identified two new risk-associated loci for prostate cancer on chromosomes 9q31.2 (rs817826, P = 5.45 × 10(-14)) and 19q13.4 (rs103294, P = 5.34 × 10(-16)) in 4,484 prostate cancer cases and 8,934 controls. 23023329

2012

dbSNP: rs103294
rs103294
C 0.730 GeneticVariation GWASCAT In addition to confirming several associations reported in other ancestry groups, this study identified two new risk-associated loci for prostate cancer on chromosomes 9q31.2 (rs817826, P = 5.45 × 10(-14)) and 19q13.4 (rs103294, P = 5.34 × 10(-16)) in 4,484 prostate cancer cases and 8,934 controls. 23023329

2012

dbSNP: rs103294
rs103294
0.730 GeneticVariation BEFREE A recent prostate cancer (PCa) genome-wide association study (GWAS) identified rs103294, a single nucleotide polymorphism (SNP) located on LILRA3, a key component in the regulation of inflammatory inhibition, to be significantly associated with PCa risk in a Chinese population. 23615473

2013

dbSNP: rs103294
rs103294
0.730 GeneticVariation BEFREE Three SNPs-rs2735839, rs10486567, and rs103294-were associated with biopsy-proven high-aggressive (GS ≥8) prostate cancer (P < 0.05). 25274378

2014

dbSNP: rs1034528
rs1034528
0.010 GeneticVariation BEFREE In the single-locus analysis, we found a significantly increased risk of PCa associated with mTOR rs2536 CT/CC and rs1034528 CG/CC genotypes [adjusted OR = 1.42 (1.13-1.78), P = 0.003 and 1.29 (1.07-1.55), P = 0.007), respectively], compared with their common homozygous genotypes, whereas mTOR rs2295080 GT/GG genotypes were associated with a decreased risk of PCa [adjusted OR = 0.76 (0.64-0.92), P = 0.003], compared with wild-type TT genotypes. 23940798

2013

dbSNP: rs1034866440
rs1034866440
AR
0.050 GeneticVariation BEFREE However, no clear consensus has been reached on the association between the SRD5A2 V89L, A49T and TA repeat polymorphisms and prostate cancer (PCa) risk. 21177315

2011

dbSNP: rs1034866440
rs1034866440
AR
0.050 GeneticVariation BEFREE Conversely, no association was observed between prostate carcinoma risk and the other polymorphisms studied as follow: the CAG repeat in exon 1 of AR, the (TA)n dinucleotide repeat polymorphism in the 3' untranslated region, and the A49T or V89L substitutions in SDR5A2, the single base pair (bp) (a T to C transition) polymorphism that creates an additional Sp1-type (CCACC box) promoter site in CYP17. 11571725

2001

dbSNP: rs1034866440
rs1034866440
AR
0.050 GeneticVariation BEFREE The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223). 16039774

2005

dbSNP: rs1034866440
rs1034866440
AR
0.050 GeneticVariation BEFREE The aim of the present study was to evaluate the distribution of polymorphisms for the androgen receptor (AR) (CAG, StuI, GGN), SRD5A2 (Ala49Thr, Val89Leu) and CYP17 (MspA1) genes that are considered to be relevant for risk of prostate cancer. 11847524

2002

dbSNP: rs1034866440
rs1034866440
AR
0.050 GeneticVariation BEFREE Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer. 12210487

2002

dbSNP: rs1041258260
rs1041258260
0.010 GeneticVariation BEFREE The aim of the present study was to analyze the effect of XPG Asp 1104His and XRCC1 Arg309Gln polymorphisms on risk of prostate cancer in north Indian population. 21670956

2012

dbSNP: rs1041449
rs1041449
G 0.700 GeneticVariation GWASCAT A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. 25217961

2014

dbSNP: rs1042489
rs1042489
0.010 GeneticVariation BEFREE The aim of this study was to investigate the possible association of c.-31G>C (rs9904341), c.454G>A (rs2071214), c.*148T>C (rs2239680) and c.*571T>C (rs1042489) polymorphisms of <i>survivin</i> gene with prostate cancer risk and provide some justification using <i>in silico</i> analysis. 30034311

2018

dbSNP: rs1042522
rs1042522
0.060 GeneticVariation BEFREE SNP309 T alleles were associated with a significantly decreased prostate cancer risk among Pro72Arg Pro </span>alleles carriers (OR=0.79, 95% CI, 0.64-0.98). 26025918

2016

dbSNP: rs1042522
rs1042522
0.060 GeneticVariation BEFREE Our study provided evidence that the P53 intron 6 G>A and R72P G>C polymorphisms were associated with a higher risk of prostate cancer in a Northern Indian population. 21565625

2011

dbSNP: rs1042522
rs1042522
0.060 GeneticVariation BEFREE Although we did not find a significant relationship between the frequency of the Arg/Pro + Pro/Pro genotype of p53 Arg72Pro and susceptibility in PC, there was a combined effect of CXCL12 GA + AA genotype and the p53 72Arg/Pro + Pro/Pro genotype on the frequency of PC. 17785557

2007